Finasteride Tablet, Film Coated
Product Images NDC 60687-428

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Finasteride (NDC 60687-428). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by American Health Packaging, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

100 Ud Carton

This is a medication packaging for Finasteride Tablets, USP with NDC number 60667-428-01 and 60687-428-01 respectively. It contains 100 tablets in a pack of 10 x 10 tablets. The rest of the text seems to be errors and not readable.*

FDA Label Image

50 Ud Carton

This is a description of the drug Finasteride, which is available in a 50 tablet pack for Rx-only use. The drug should not be used by women or children, and women who may be pregnant should avoid using it. Each film-coated tablet contains 0.97mg of the active ingredient. The suggested dosage for adults is 1 to 5 mg per day. The drug should be stored between 20°C to 25°C and protected from heat. The drug product is manufactured and distributed by Aurobindo Pharma USA Inc., and the packaging is done by Richmond & Packaging Inc.*

FDA Label Image

Ahp 428 01 65

FDA Label Image

Blister

This appears to be a list of different variations of Finasteride tablets in different doses and under different brand names, with associated lot numbers and expiry dates for each.*

FDA Label Image

Figure 1

FDA Label Image

Figure 2

This appears to be a part of a research study that includes a graph (Figure 2) indicating the percentage of patients, who underwent surgery for BPH, over a period of observation time (in months) in two groups - those who received Finasteride and those who received a placebo. The graph shows that the percentage of patients who had surgery for BPH in the Finasteride group was lower than the percentage in the placebo group. The text also includes some numerical data related to the number of events and the number of patients at risk in both the groups.*

FDA Label Image

Figure 3

This is a graph showing the percentages of patients who developed acute urinary retention over a period of 24 months. Two groups are being compared - placebo group and Finasteride group. At the end of 24 months, 16% of patients in the placebo group developed acute urinary retention while only 2% of patients in the Finasteride group developed it. The graph also shows the number of patients at risk over time and the number of events (urinary retention) that occurred at different time points.*

FDA Label Image

Figure 4

FDA Label Image

Figure 5

This is a graph showing the Cumulative Incidence of a 4-Point Rise in AUA Symptom Score by Treatment Group. The percent of people with an event is plotted on the Y-axis while the years from randomization are plotted on the X-axis.*

FDA Label Image

Structure

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.